Siegert W, Hiddemann W, Koppensteiner R, Büchner T, Essink M, Huhn D, Jung M, Marosi L, Martin T, Minar E
Medizinische Klinik und Poliklinik, Klinikum Rudolf Virchow, Freie Universität Berlin, F.R.G.
Med Oncol Tumor Pharmacother. 1989;6(4):275-8. doi: 10.1007/BF02985161.
Mitoxantrone is a new effective antineoplastic agent with activity against a wide range of tumors. Compared with the anthracycline drugs doxo- and daunorubicin, it exhibits a clearly lower toxicity and, most importantly, a reduced cardiotoxicity. The analysis of the side-effects recorded after accidental overdosage of the drug gives additional insight into its tolerability. Here we describe our observations in three patients who inadvertently received 100 mg m-2 (two pts) and 183 mg m-2 (one pt) as single slow bolus injections. The main side-effects were moderate nausea and vomiting, shaking chills, and profound but reversible neutro- and thrombocytopenia. There was no immediate cardiac toxicity. One patient with extensive previous daunomycin exposure developed congestive heart failure after 4 months. Two patients were not evaluable for late cardiac complications because of early death due to tumor progression.
米托蒽醌是一种新型有效的抗肿瘤药物，对多种肿瘤具有活性。与蒽环类药物阿霉素和柔红霉素相比，它的毒性明显更低，最重要的是，心脏毒性降低。对该药物意外过量使用后记录的副作用进行分析，可进一步了解其耐受性。在此，我们描述了3例患者的观察结果，这些患者无意中单次缓慢推注了100mg/m²（2例）和183mg/m²（1例）的药物。主要副作用为中度恶心、呕吐、寒战以及严重但可逆的中性粒细胞减少和血小板减少。无即刻心脏毒性。1例既往曾大量使用柔红霉素的患者在4个月后发生充血性心力衰竭。2例患者因肿瘤进展早期死亡，无法评估晚期心脏并发症。
